IDEXX Laboratories, Inc.
515.15USD
-5.0600 (-0.97%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $3.71▼ | $3.78 | 3 | 7 |
| Next quarter | $3.37▼ | $3.45 | 1 | 8 |
| Current year | $14.83▲ | $14.67 | 11 | 0 |
| Next year | $16.74▲ | $16.52 | 11 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $3.93 | $4.27 | +0.34 (+8.5%) |
| 2026-03-31 | $3.41 | $3.47 | +0.06 (+1.7%) |
| 2025-12-31 | $2.94 | $3.08 | +0.14 (+4.8%) |
| 2025-09-30 | $3.15 | $3.4 | +0.25 (+8.1%) |
130 ratings from 19 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Maintained | Overweight | $800 $710 | Aug 11, 2026 |
| UBS | Maintained | Neutral | $620 $670 | Aug 5, 2026 |
| Citigroup | Maintained | Neutral | $650 $670 | Aug 5, 2026 |
| UBS | Maintained | Neutral | $640 $620 | Jul 27, 2026 |
| UBS | Maintained | Neutral | $730 $640 | Apr 28, 2026 |
| Citigroup | Initiated | Neutral | $650 | Apr 15, 2026 |
| Stifel | Maintained | Buy | $775 $675 | Mar 31, 2026 |
| Piper Sandler | Maintained | Neutral | $775 $750 | Feb 9, 2026 |
| Barclays | Maintained | Overweight | $850 $800 | Feb 5, 2026 |
| UBS | Maintained | Neutral | $750 $730 | Feb 3, 2026 |
| BTIG | Maintained | Buy | $830 $800 | Feb 3, 2026 |
| Barclays | Initiated | Overweight | $850 | Dec 9, 2025 |
| Morgan Stanley | Maintained | Overweight | $765 $805 | Nov 4, 2025 |
| UBS | Maintained | Neutral | $710 $750 | Nov 4, 2025 |
| JP Morgan | Maintained | Overweight | $675 $775 | Nov 4, 2025 |
| BTIG | Maintained | Buy | $785 $830 | Nov 4, 2025 |
| Stifel | Upgraded from Hold | Buy | $640 $700 | Oct 31, 2025 |
| UBS | Initiated | Neutral | $720 | Oct 1, 2025 |
| Morgan Stanley | Maintained | Overweight | $722 $765 | Aug 15, 2025 |
| Piper Sandler | Maintained | Neutral | $510 $700 | Aug 11, 2025 |
| JP Morgan | Maintained | Overweight | $550 $675 | Aug 4, 2025 |
| Morgan Stanley | Maintained | Overweight | $626 $722 | Aug 4, 2025 |
| Morgan Stanley | Maintained | Overweight | $548 $628 | Jul 29, 2025 |
| Leerink Partners | Maintained | Outperform | $580 $600 | Jul 17, 2025 |
| Stifel | Maintained | Hold | $510 $540 | Jul 2, 2025 |
90 filings from 20 insiders · 0 buy / 0 sell over 6m
Officers and directors of IDXX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kingsley Lawrence DDirector | ExerciseNon-Qualified Stock Option (right-to-buy) | 2.2k | — | — | Sep 4, 2026 |
| Kingsley Lawrence DDirector | Sell | 2.2k | $532.08 | $1.17M | Sep 4, 2026 |
| Kingsley Lawrence DDirector | Exercise | 2.2k | $114.17 | $252k | Sep 4, 2026 |
| EMERSON ANDREWChief Financial Officer | Exercise | 265 | $178.26 | $47k | Aug 20, 2026 |
| HOOLEY JOSEPH L.Director | Grant | 49 | $558.80 | $27k | Jul 30, 2026 |
| FENNELL GEORGEOfficer | Other | 639 | — | — | Jun 1, 2026 |
| VANDEBROEK SOPHIE VDirector | Other | 257 | — | — | May 7, 2026 |
| KINGSLEY LAWRENCE DDirector | Other | 339 | — | — | May 7, 2026 |
| HOOLEY JOSEPH L.Director | Other | 158 | — | — | May 7, 2026 |
| PEACOCK KARENDirector | Other | 101 | — | — | May 7, 2026 |
| JUNIUS DANIEL MDirector | Other | 257 | — | — | May 7, 2026 |
| SZOSTAK MARGARET ANNEDirector | Other | 257 | — | — | May 7, 2026 |
| HOOLEY JOSEPH L.Director | Grant | 43 | $560.80 | $24k | Apr 30, 2026 |
| HUNT NIMRATA KOfficer | Sell | 1.8k | $634.57 | $1.12M | Mar 3, 2026 |
| UNDERBERG SHARON EGeneral Counsel | Exercise | 197 | $505.53 | $100k | Mar 3, 2026 |
| MAZELSKY JONATHAN JAYChief Executive Officer | Exercise | 23.5k | $141.60 | $3.40M | Feb 27, 2026 |
| HUNT NIMRATA KOfficer | Sell | 2.7k | $661.54 | $1.78M | Feb 26, 2026 |
| MAZELSKY JONATHAN JAYChief Executive Officer | Sell | 23.3k | $650.67 | $15.34M | Feb 26, 2026 |
| ERICKSON MICHAEL GOfficer | Exercise | 7.8k | $141.60 | $1.46M | Feb 19, 2026 |
| ERICKSON MICHAEL GOfficer | Sell | 5.4k | $623.76 | $3.37M | Feb 17, 2026 |
No analyst notes on IDXX yet.
Analyst Ratings
13 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 4 | 4 | 5 | 0 | 1 | Buy2.29 |
| 1 mo ago | 4 | 4 | 5 | 0 | 1 | Buy2.29 |
| 2 mo ago | 4 | 5 | 5 | 0 | 1 | Buy2.27 |
| 3 mo ago | 4 | 5 | 5 | 0 | 1 | Buy2.27 |